Neuvivo and the FDA have agreed on a regulatory pathway for NP001 (sodium chlorite) to treat ALS, with Phase 3 testing ...

In ALS, the loss of certain proteins turns off a gene called UNC13A that needs to stay active for nerve cell communication, a ...

Patient randomization is nearly complete in Medicinova’s Phase 2b/3 COMBAT-ALS trial testing MN-166 (ibudilast) for the ...

Answer ALS is backing a Louisiana collaboration aimed at using AI to accelerate drug discovery for ALS and other ...

Completing a project in her backyard was satisfying for columnist Kristin Neva, whose work as an ALS caregiver is repetitive and ongoing.

The ongoing EAP that is providing ALS patients with access to MN-166 (ibudilast) outside of a clinical trial is adding more ...

Columnist Dagmar Munn feels as if she's finding her voice again as she picks up her speech exercises, and then some.

AB Science's new Phase 3 trial of masitinib for ALS has been cleared to launch in certain European countries, as well as in ...

CB03-154 is a newer ALS therapy that's designed to open nerve cells' KCNQ2 and KCNQ3 potassium channels without affecting other ion channels.

ALS is a progressive neurological disorder that damages motor neurons. Learn more about types, causes, symptoms, diagnosis, and treatment.

Columnist Kristin Neva shares what she feels has worked and not worked in terms of slowing her husband's ALS progression over 15 years.